<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR87">
 <label>87.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Jackisch</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Kim</surname>
    <given-names>SB</given-names>
   </name>
   <name>
    <surname>Semiglazov</surname>
    <given-names>V</given-names>
   </name>
   <name>
    <surname>Melichar</surname>
    <given-names>B</given-names>
   </name>
   <name>
    <surname>Pivot</surname>
    <given-names>X</given-names>
   </name>
   <name>
    <surname>Hillenbach</surname>
    <given-names>C</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study</article-title>
  <source>Ann Oncol</source>
  <year>2015</year>
  <volume>26</volume>
  <fpage>320</fpage>
  <lpage>325</lpage>
  <pub-id pub-id-type="doi">10.1093/annonc/mdu524</pub-id>
  <?supplied-pmid 25403587?>
  <pub-id pub-id-type="pmid">25403587</pub-id>
 </element-citation>
</ref>
